Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia

Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia

This research is aimed to study the possibility of management of severe symptoms of overactive bladder (OAB) with solifenacin and trospium in patients who receive treatment with tamsulosin due to benign prostatic hyperplasia (BPH). The 338 men more than 50 years old (average age 58.4 years) diagnose...

Full description

Bibliographic Details
Main Authors:	Kirill Vladimirovich Kosilov MD, PhD, Sergay A. Loparev MD, Marina A. Ivanovskaya MD, PhD, Liliya V. Kosilova MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-03-01
Series:	American Journal of Men's Health
Online Access:	https://doi.org/10.1177/1557988315595692

Similar Items

Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance
by: Kirill V. Kosilov, et al.
Published: (2014-12-01)

Re: Comparative Effectiveness of Combined Low- and Standart-Dose Trospium and Solifenacin for Moderate Overactive Bladder Symptoms in Elderly Men and Women
by: Kirill V. Kosilov, et al.
Published: (2015-03-01)

Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence
by: Kirill Kosilov, et al.
Published: (2018-03-01)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
by: Kirill Kosilov, et al.
Published: (2013-12-01)

Factors of adherence to treatment with trospium in employees
by: Kirill Vladimirovich Kosilov, et al.
Published: (2017-09-01)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
by: Kirill V. Kosilov, et al.
Published: (2020-06-01)

Solifenacin in overactive bladder syndrome: pharmacoeconomic analysis
by: Sergio Iannazzo, et al.
Published: (2008-03-01)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
by: Stacey Tannenbaum, et al.
Published: (2020-12-01)

Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany
by: Murgas S, et al.
Published: (2019-01-01)

Comparison of objective and subjective factors in the adherence to antimuscarinics when treating overactive bladder in employed persons
by: Kirill Vladimirovich Kosilov, et al.
Published: (2017-12-01)

A Prospective, Comparative Study of the Occurrence and Severity of Constipation with Darifenacin and Trospium in Overactive Bladder
by: Revanna Manjunatha, et al.
Published: (2015-03-01)

Solifenacin and Tolterodine are Equally Effective in the Treatment of Overactive Bladder Symptoms
by: Chen-Hsun Ho, et al.
Published: (2010-10-01)

Bilateral spontaneous urinary extravasation shown by computed tomography urography in a patient with benign prostatic hyperplasia
by: Haopeng Pang, MD, PhD, et al.
Published: (2015-12-01)

The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment
by: Eric Chieh-Lung Chou, et al.
Published: (2014-08-01)

Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors
by: Kirill Vladimirovich Kosilov, et al.
Published: (2017-03-01)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
by: Farida van Rey, et al.
Published: (2011-01-01)

Social, Economic, and Medical Factors Associated With Solifenacin Therapy Compliance Among Workers Who Suffer From Lower Urinary Tract Symptoms
by: Kirill Vladimirovich Kosilov, et al.
Published: (2016-09-01)

Overactive bladder symptoms recurrence after sudden versus gradual weaning of Solifenacin
by: Ahmed Abdelbary, et al.
Published: (2020-12-01)

Solifenacin may improve sleep quality in patients with overactive bladder and sleep disturbance
by: T Takao, et al.
Published: (2011-10-01)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
by: Yankai Xu, et al.
Published: (2017-09-01)

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
by: Naoya Masumori, et al.
Published: (2010-01-01)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
by: Christopher R. Chapple, et al.
Published: (2016-12-01)

Maternal fructose exposure programs metabolic syndrome-associated bladder overactivity in young adult offspring
by: Wei-Chia Lee, M.D. Ph.D., et al.
Published: (2016-06-01)

Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
by: Michael J. Schoenfeld MA, et al.
Published: (2014-05-01)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
by: Zalmai Hakimi, et al.
Published: (2018-01-01)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
by: Ji-Youn Chun, et al.
Published: (2014-03-01)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
by: Seong Cheol Kim, et al.
Published: (2021-05-01)

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study.
by: Yumeng Zhang, et al.
Published: (2021-01-01)

Is Effective in the Treatment of Benign Prostatic Hyperplasia?
by: Gökhan Çeker MD
Published: (2020-06-01)

PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Development, optimization and pharmacokinetic evaluation of biphasic extended-release osmotic drug delivery system of trospium chloride for promising application in treatment of overactive bladder
by: Ramakanth Gundu, et al.
Published: (2021-08-01)

Compared Cost-Effectiveness of Solifenacin with Other Antimuscarinics in Patients with Overactive Bladder Symptoms: Systematic Reviews and Meta-Analysis
by: Yu-Cheng Chang, et al.
Published: (2017)

The impact of adding solifenacin to tamsulosin therapy for treatment of storage lower urinary tract symptoms owing to benign prostatic hyperplasia
by: Mohamed Elbadry, et al.
Published: (2020-12-01)

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
by: Tong Cai, et al.
Published: (2020-12-01)

The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience)
by: Nibbras I. AL-Hamdani, et al.
Published: (2015-07-01)

Updated strategies in the treatment of benign diseases—a patterns of care study of the german cooperative group on benign diseases
by: Jan Kriz, MD, et al.
Published: (2018-07-01)

A Case of C-Cell Hyperplasia in an Asymptomatic V804M Ret Mutation Carrier: Can the Calcium Infusion Test Predict C-Cell Hyperplasia?
by: Maiko Kakita-Kobayashi, MD, et al.
Published: (2015-01-01)

Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
by: Dimitropoulos K, et al.
Published: (2015-03-01)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
by: Se Yun Kwon, et al.
Published: (2020-07-01)

Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study
by: A. Ivchenko, et al.
Published: (2018-09-01)